2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6283 Disparities in real-world conditional survival of adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL)

Jerry Luo, MD, MS, Theresa H Keegan, MD, PhD2, Helen Parsons, PhD, MPH3, Katharine Miller, PhD, MPH4, Lori Muffly, MD5
1 Stanford University School of Medicine, Palo Alto, California, United States
2 University of California Davis, Davis, California, United States
3 University of Minnesota, Minneapolis, Minnesota, United States
4 Stanford University School of Medicine, Palo Alto, California, United States
5 Stanford University School of Medicine, Palo Alto, California, United States
Background
Adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated at specialized cancer centers (SCC) have superior outcomes; however, fewer than half of AYAs receive such care, particularly those with public insurance. Traditional survival estimates calculated from the date of diagnosis do not reflect the evolving prognosis of patients who survive intensive chemotherapy, transition to maintenance treatment, and enter survivorship. Conditional survival (CS) is a clinically relevant, dynamic estimate defined as the probability of surviving an additional interval of time, given survival to a defined time point. While CS is known to improve over time in ALL, whether it differs by treatment setting, insurance, or other sociodemographic factors is less well studied. We therefore calculated the 5-year CS of AYAs with newly diagnosed ALL at each of the first five years after diagnosis to determine whether disparities in CS exist and how they evolve over time.

Methods
We identified AYAs aged 15–39 years with newly diagnosed ALL during 2004–2018 from California, New York, and Texas state cancer registries. SCC was defined as an NCI-designated Cancer Center or Children's Oncology Group site, determined by the registry-reported treating facility. Follow-up was measured from the date of diagnosis to death from any cause, with patients censored at the time of last contact. Five-year unadjusted CS was calculated using life table methods at 1, 2, 3, 4, and 5 years after diagnosis for the overall cohort and stratified by treatment setting (SCC vs non-SCC), insurance status at diagnosis (private, public, uninsured), age group (15–25, 26–39), and neighborhood poverty quintile.

Results
We included 4,348 AYAs with newly diagnosed ALL in our analysis. A minority (41%) received care at an SCC. Most (60%) were aged 15–25 years, and 40% were aged 26–39 years. Among those with known insurance type, 49% had private insurance, 45% public, and 6% were uninsured. The distribution across neighborhood poverty quintiles ranged from 15% to 25%, with the highest proportion in the lowest-income quintile. In the overall cohort and every subgroup, 5-year CS increased with each additional year of survival.

Five-year CS (95% CI) was higher for AYAs treated at SCCs than at non-SCCs at years 1 to 3, converging by years 4 and 5. Among those alive at 1 year, 5-year CS was 16 percentage points higher at SCCs (76% [70–81]) than at non-SCCs (60% [55–65]). This gap narrowed to 8 points at 2 years (82% [77–88] vs 74% [69–80]) and 4 points at 3 years (86% [81–92] vs 82% [77–87]). Five-year CS was similar in years 4 (88% [82–94] vs 88% [83–93]) and 5 (91% [87–96] vs 92% [88–96]).

Among insurance subgroups, 5-year CS was higher for privately insured AYAs than for publicly insured and uninsured AYAs for every year survived. At 1 year, 5-year CS was 13 percentage points higher for privately than publicly insured AYAs (74% vs 61%). With each subsequent year survived, this difference narrowed to 10 (82% vs 72%), 7 (88% vs 80%), 5 (91% vs 85%), and 3 points (93% vs 90%) at years 2, 3, 4, and 5, respectively. For uninsured AYAs, 5-year CS increased from 55% (40–73) at year 1 to 73% at year 2 and was similar to that of publicly insured AYAs in years 3–5.

Lower neighborhood income was associated with lower 5-year CS, and this difference attenuated with time. At year 1, CS was 15 percentage points higher in the highest-income quintile (76%) than in the lowest-income quintile (61%). This gap decreased to 12 (84% vs 72%), 8 (88% vs 80%), 7 (91% vs 85%), and 5 points (94% vs 88%) at years 2, 3, 4, and 5, respectively. Younger AYAs (15–25 years old) had higher 5-year CS than older AYAs (26–39) for all years survived. There was a 15 percentage-point difference among 1-year survivors (72% vs 57%), which narrowed to 4 points by year 5 (93% vs 89%).

Conclusion
In our cohort of AYAs with newly diagnosed ALL, disparities in 5-year CS by treatment setting, insurance, and neighborhood poverty quintile were largest early after diagnosis and narrowed among longer-term survivors, though insurance and poverty differences persisted. Together with our prior finding that uninsured AYAs are less likely to receive care at SCCs, these results reinforce that the period around diagnosis is a critical window for referral to specialized care. Policies that expand access to specialized centers for AYAs, particularly the uninsured, may help address these early survival disparities.
Jerry Luo, MD, MS: No relevant conflicts of interest to declare.